Ieramilimab
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors[1].
Product Specifications
CAS Number
2137049-37-5
Product Name Alternative
LAG525; IMP701; Hu5A8
UNSPSC
12352203
Target
LAG-3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ieramilimab.html
Purity
98.24
Solubility
H2O
Smiles
[Ieramilimab]
Molecular Weight
(146.78 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CXCL10 (IP-10, C-X-C Motif Chemokine 10, 10kD Interferon gamma-induced Protein, Gamma-IP10, Small-inducible Cytokine B10, INP10, SCYB10) (PE)
Lentiviral human MRPL27 shRNA (UAS) - Lentiviral human MRPL27 shRNA (UAS, iRFP) (25)
